The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Haven't checked in here in awhile but I see no progress except Artemic into India? Cimetras approval for India has been around 133 days so im guessing it's flopped considering it was supposed to take 90?
Did anything happen with the cis countries, Russia or Canada?
"The trial is expected to commence in the coming week and conclude around September 2021 with results then available in October 2021"
Cimetra RNS 13th july
"Phase II clinical trial for CogniCann? at the University of Notre Dame, Perth has already
recruited 21 of 50 patients and interim results are expected in Q4 2021."
Cognicanm 25th may RNS
"The study drug import process has commenced following Israeli Ministry of Health approval. The trial will be initiated
in July and the first patient is expected to be enrolled in September 2021. Interim results of the trial are expected in Q4
2021.
MGC has already initiated a Driving Safety study of CannEpil® in Australia following the reopening of universities after
the COVID-19 lockdowns. This trial involves healthy volunteers and aims to demonstrate the safety of CannEpil® in order
to provide supportive data to the regulatory authorities.
The first patient is expected to be recruited in June 2021 and 31 patients are expected to be recruited in October 2021."
Cannepil 25th may RNS.
Cimetra is late and CogniCann and CannEpil haven't even started/resumed.
Don't even wanna get started on Canada and India but nothing with this company runs on time.
Do you actually expect results in Feb? How late are they on everything else?
Does anyone know what qualification(s) Jeff Bezos has in regard to business?
Article from December 2nd
"Without emergency approval, MGC is reportedly on track to achieve ‘cash flow breakeven status… very quickly’, with more company announcements set to be released in the coming days"
https://businesscann.com/mgc-pharmaceuticals-tells-shareholders-pending-deal-could-transform-finances-overnight/
Id be saying India won't happen until next year.
Watch at 3:10
https://www.proactiveinvestors.co.uk/companies/amp/news/967962
90 days tomorrow since the Indian announcement. If everything has gone to plan should hopefully have an announcement within the next 2 weeks.
I doubt we get any interim results posted so im going to take this as the next best thing -
"CimetrA™, MGC's proprietary nanoparticle micellar formulation is in clinical trials and has demonstrated its safety and effectiveness as a treatment for COVID-19 patients in both mild and severe cases."
What for?
It's for a capital raise - "pending the release of an announcement by the Company in relation to a capital raising."
Expecting anything from it?
Should hopefully get some positive news about India in 2-4 weeks...as long as the 90 days process is correct
No point to any of your posts. Someone following a stock for 3 years to only put it down says about all you need to know.
Has anyone ever asked smlfry why he has spent 3 years being salty over MGC? Got a crush on Roby but it wasn't reciprocated?
https://hotcopper.com.au/search/4688201/?page=7&q=%2A&t=post&o=relevance&c[visible]=true&c[user][0]=317459
What RNS is this? All i see is the one about unquoted shares
Next news should hopefully be India at the start of next month. Hopefully orders from that are significant enough to cover costs and put any fears to bed. Then ill put this share in the back pocket and revisit every few months to check on clinical trials.
Yeah sick breakout.....charts are trash. TA is trash.
Only deals, progress and money will move the share price.
These charts mean nothing. Only thing that will move the price is money being made and the conpany being successful.
India has around 26 days left of their approval process by my count. Hopefully by the end of the year we will know if Cimetra is going to be a positive or not.
The only thing mentioned about Russia in the quarterly and annual statement was:
"During the year, funds were loaned to an unrelated entity to advance registration of its phytomedicine products in Russia
and CIS countries, interest-bearing and repayable in 24 months. MGC Pharma is party to a draft agreement to acquire a
54% interest in this entity for nominal consideration, with finalisation of the transaction subject to signing and physical
lodgement of the share transfer document in the country of incorporation, expected to occur in the coming months.
The loan has been classified as a financial asset at fair value through profit or loss, with a fair value determined to be nil
at 30 June 2021 due to the equity risk associated with the loan."